Basilea Pharmaceutica AG
BPMUF
$67.75
$6.4110.45%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 244.71M | 230.37M | 221.94M | 192.11M | 161.32M |
| Total Other Revenue | 27.87M | 21.38M | 15.63M | 11.23M | 6.74M |
| Total Revenue | 272.58M | 251.75M | 237.56M | 203.33M | 168.05M |
| Cost of Revenue | 146.23M | 136.93M | 131.73M | 136.55M | 140.92M |
| Gross Profit | 126.35M | 114.82M | 105.83M | 66.78M | 27.13M |
| SG&A Expenses | 38.13M | 36.13M | 35.25M | 35.16M | 34.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.37M | 173.06M | 166.98M | 171.71M | 175.87M |
| Operating Income | 88.22M | 78.70M | 70.58M | 31.62M | -7.81M |
| Income Before Tax | 83.22M | 75.55M | 68.98M | 26.75M | -15.97M |
| Income Tax Expenses | -381.00K | -9.94M | -19.58M | -17.36M | -15.10M |
| Earnings from Continuing Operations | 83.61 | 85.49 | 88.56 | 44.11 | -0.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.61M | 85.49M | 88.56M | 44.11M | -861.60K |
| EBIT | 88.22M | 78.70M | 70.58M | 31.62M | -7.81M |
| EBITDA | 90.89M | 81.29M | 73.14M | 34.19M | -5.26M |
| EPS Basic | 6.89 | 7.07 | 7.33 | 3.65 | -0.08 |
| Normalized Basic EPS | 4.29 | 3.90 | 3.57 | 1.38 | -0.83 |
| EPS Diluted | 6.29 | 6.48 | 6.70 | 3.23 | -0.28 |
| Normalized Diluted EPS | 3.75 | 3.42 | 3.12 | 1.13 | -0.87 |
| Average Basic Shares Outstanding | 48.67M | 48.46M | 48.31M | 48.22M | 48.13M |
| Average Diluted Shares Outstanding | 55.47M | 54.48M | 54.46M | 52.57M | 50.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |